Prevention and treatment of nonalcoholic fatty liver disease (NAFLD) by antagonism of the receptor to glucose-dependent insulinotropic polypeptide (GIP)
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
Feb 12, 2004
app pub date -
Jun 13, 2003
filing date -
Jun 15, 2002
priority date (Note) -
Abandoned
status (Latency Note)
Importance
Abstract
The present invention concerns the use of various forms of GIP-receptor antagonists to attenuate the insulin response to GIP following meals in animals, such as humans, to prevent, reduce, inhibit and/or treat nonalcoholic fatty liver disease by virtue of its prevention and/or reversal of hyperinsulinemia and insulin resistance. Thus, the use of the GIP-receptor antagonists in any effective form is believed to prevent the development and reverse the process of NAFLD. The present invention is accomplished by administering an effective amount of an antagonistic agent, such as a GIP antagonist or an antisense molecule, to antagonize, block, inhibit or ablate the receptor to Glucose-Dependent Insulinotropic Polypeptide (GIP).
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully